COSCIENS Biopharma Inc (CSCI)

[Miraclestock]

Where are publications like Seeking Alpha, Motley Fool, Zacks, etc. They should be writing about recent very positive developments with Macrilen. Macrilen pricing is now double the price per patient than originally anticipated as per Strongbridge biopharma CEO. Also, the patient population in which Macrilen is being used is beyond simply AGHD patients but is also being used for Traumatic Brain injury (TBI) patients as well. There are about 600,000-700,000 eligible TBI patients per year potentially for Macrilen in just the USA and Canada alone. Thus, the pricing and patient population are much higher than the older estimates and therefore new coverage by analysts should be initiated on AEZS to explain the new valuation of Macrilen and also upgrade the outdated price targets as well.